ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718,811 | -21.0% | 20,163 | +2.2% | 0.01% | -14.3% |
| Q2 2023 | $909,776 | +17.6% | 19,722 | +2.2% | 0.01% | 0.0% |
| Q1 2023 | $773,810 | -11.0% | 19,297 | +2.8% | 0.01% | -12.5% |
| Q4 2022 | $869,799 | +16.3% | 18,774 | +4.0% | 0.01% | 0.0% |
| Q3 2022 | $748,000 | -29.8% | 18,053 | +1.1% | 0.01% | -20.0% |
| Q2 2022 | $1,066,000 | -16.1% | 17,863 | +2.1% | 0.01% | 0.0% |
| Q1 2022 | $1,271,000 | -12.9% | 17,504 | +0.9% | 0.01% | -9.1% |
| Q4 2021 | $1,459,000 | -7.4% | 17,345 | -0.7% | 0.01% | -15.4% |
| Q3 2021 | $1,575,000 | -4.5% | 17,463 | +1.0% | 0.01% | 0.0% |
| Q2 2021 | $1,649,000 | -20.8% | 17,289 | -5.5% | 0.01% | -27.8% |
| Q1 2021 | $2,083,000 | -9.9% | 18,295 | +9.6% | 0.02% | -14.3% |
| Q4 2020 | $2,311,000 | +64.1% | 16,693 | -2.5% | 0.02% | +50.0% |
| Q3 2020 | $1,408,000 | +45.0% | 17,128 | +38.0% | 0.01% | 0.0% |
| Q2 2020 | $971,000 | +69.8% | 12,413 | -3.7% | 0.01% | +40.0% |
| Q1 2020 | $572,000 | – | 12,884 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |